162 related articles for article (PubMed ID: 10651734)
21. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
[TBL] [Abstract][Full Text] [Related]
22. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
24. Importance of mixed chimerism to predict relapse in persistently BCR/ABL positive long survivors after allogeneic bone marrow transplantation for chronic myeloid leukemia.
Román J; Martín C; Torres A; García A; Andrés P; García MJ; Baiget M
Leuk Lymphoma; 1998 Feb; 28(5-6):541-50. PubMed ID: 9613984
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy.
Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL
Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754
[TBL] [Abstract][Full Text] [Related]
26. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation.
Eder M; Battmer K; Kafert S; Stucki A; Ganser A; Hertenstein B
Leukemia; 1999 Sep; 13(9):1383-9. PubMed ID: 10482989
[TBL] [Abstract][Full Text] [Related]
28. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia.
Mackinnon S; Barnett L; Heller G; O'Reilly RJ
Blood; 1994 Jun; 83(11):3409-16. PubMed ID: 8193379
[TBL] [Abstract][Full Text] [Related]
29. Comparative Study of FISH, PCR and Cytogenetics on 25 Patients Submitted to Bone Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML); Which Tests can we Use in Routine Analysis Post BMT?
Palka G; Lawler M; Morizio E; Gardiner N; Stuppia L; De Arce MA; Di Bartolomeo PD; Capodiferro F; Sabatino G; Gatta V; Calabrese G; Cann SR
Hematology; 1998; 3(3):193-203. PubMed ID: 27416528
[TBL] [Abstract][Full Text] [Related]
30. Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Leda M; Ladon D; Pieczonka A; Boruczkowski D; Jólkowska J; Witt M; Wachowiak J
Leuk Res; 2001 Apr; 25(4):353-7. PubMed ID: 11248334
[TBL] [Abstract][Full Text] [Related]
31. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.
Branford S; Hughes TP; Rudzki Z
Br J Haematol; 1999 Dec; 107(3):587-99. PubMed ID: 10583264
[TBL] [Abstract][Full Text] [Related]
32. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation.
Raanani P; Dazzi F; Sohal J; Szydlo RM; van Rhee F; Reiter A; Lin F; Goldman JM; Cross NC
Br J Haematol; 1997 Dec; 99(4):945-50. PubMed ID: 9432048
[TBL] [Abstract][Full Text] [Related]
33. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Tabayashi T; Yamada K; Takeuchi M
Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
[TBL] [Abstract][Full Text] [Related]
34. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
35. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
[TBL] [Abstract][Full Text] [Related]
36. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Dazzi F; Szydlo RM; Cross NC; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; Yong A; Apperley JF; Goldman JM
Blood; 2000 Oct; 96(8):2712-6. PubMed ID: 11023502
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation.
Flowers ME; Leisenring W; Beach K; Riddell S; Radich JP; Higano CS; Rowley SD; Chauncey TR; Sanders JE; Anasetti C; Storb R; Wade J; Appelbaum FR; Martin P
Biol Blood Marrow Transplant; 2000; 6(3A):321-6. PubMed ID: 10905769
[TBL] [Abstract][Full Text] [Related]
38. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation.
Castro FA; Palma PV; Morais FR; Voltarelli JC
Braz J Med Biol Res; 2004 Feb; 37(2):201-6. PubMed ID: 14762574
[TBL] [Abstract][Full Text] [Related]
39. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Hertenstein B; Wiesneth M; Novotny J; Bunjes D; Stefanic M; Heinze B; Hübner G; Heimpel H; Arnold R
Transplantation; 1993 Nov; 56(5):1114-8. PubMed ID: 8249110
[TBL] [Abstract][Full Text] [Related]
40. Rapid clonal development in a relapsed CML 11 years post replete allogeneic bone marrow transplantation.
Kearney P; Suter M; Biggs JC
Leuk Res; 2002 Jan; 26(1):111-5. PubMed ID: 11734309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
